World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
123
Citations
62212
World Ranking
3320
National Ranking
92

Hervé Tilly publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hervé Tilly sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 756 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hervé Tilly D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hervé Tilly sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 123 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hervé Tilly is affiliated with the University of Rouen in France and has a significant body of research primarily within the field of Medicine. Their scholarly output covers a range of subfields including Pathology and Forensic Medicine, Oncology, Genetics, Pulmonary and Respiratory Medicine, and Cancer Research. The work extends across multiple specialized topics such as Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Lung Cancer Treatments and Mutations.

Their research has appeared frequently in notable publication venues, with the highest number of papers published in Blood. Other significant journals of publication include Hematological Oncology, Journal of Clinical Oncology, HemaSphere, and Clinical Lymphoma Myeloma & Leukemia.

Frequent co-authorships feature collaborations with several researchers, including Franck Morschhauser, Olivier Casasnovas, Corinne Haïoun, Catherine Thiéblemont, and Fabrice Jardin. These partnerships reflect ongoing research networks within hematology and oncology.

Among their recent and cited papers are:

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial (2020, The Lancet Oncology)
  • International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI (2020, Blood)
  • High total metabolic tumor volume at baseline predicts survival independent of response to therapy (2020, Blood)
  • Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study (2020, Haematologica)
  • Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study (2024, The Lancet Haematology)

Best Publications

  • CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    Bertrand Coiffier;Eric Lepage;Josette Briere;Raoul Herbrecht

  • Follicular lymphoma international prognostic index.

    Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White

  • Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    P Feugier;A. Van Hoof;C. Sebban;P. Solal-Celigny

  • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

    Bertrand Coiffier;Catherine Thieblemont;Eric Van Den Neste;Gérard Lepeu

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

    Gilles Salles;John Francis Seymour;Fritz Offner;Armando Lopez-Guillermo

  • TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

    Cyril Quivoron;Cyril Quivoron;Cyril Quivoron;Lucile Couronné;Lucile Couronné;Lucile Couronné;Véronique Della Valle;Véronique Della Valle;Véronique Della Valle;Cécile K. Lopez;Cécile K. Lopez;Cécile K. Lopez

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    H Tilly;M Gomes da Silva;U Vitolo;A Jack

  • Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

    P Brice;Y Bastion;E Lepage;N Brousse

  • Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

    Nicolas Mounier;Josette Briere;Christian Gisselbrecht;Jean-Francois Emile

  • Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas

    Christian Gisselbrecht;Philippe Gaulard;Eric Lepage;Bertrand Coiffier

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • LAZ3 , a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas

    Jean-Pierre Kerckaert;Clotilde Deweindt;Hervé Tilly;Sabine Quief

  • Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

    Corinne Haioun;Eric Lepage;Christian Gisselbrecht;Gilles Salles

  • Treatment of Older Patients with Mantle-Cell Lymphoma

    H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  • Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

    Frédéric Peyrade;Fabrice Jardin;Catherine Thieblemont;Antoine Thyss

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

    Karim Belhadj;Felix Reyes;Jean-Pierre Farcet;Herve Tilly

  • An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

    T. E. Witzig;Julie Marie Vose;P. L. Zinzani;C. B. Reeder

  • Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

    Hervé Tilly;Eric Lepage;Bertrand Coiffier;Michel Blanc

Frequent Co-Authors

Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Bertrand Coiffier
Bertrand Coiffier Centre Hospitalier Lyon Sud
Olivier Casasnovas
Olivier Casasnovas Grenoble Alpes University
Philippe Gaulard
Philippe Gaulard Université Paris Cité
Christian Gisselbrecht
Christian Gisselbrecht Université Paris Cité
Thierry Jo Molina
Thierry Jo Molina Université Paris Cité
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Christian Recher
Christian Recher Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Medicine but seeking alternative or flexible educational routes, there are several online degrees and career pathways worth exploring. Many students choose nursing as a practical entry point into healthcare, and there are direct entry nursing programs designed for those who hold non-nursing bachelor’s degrees.

Advancing further, candidates without a nursing background can take advantage of direct msn programs online, which offer a fast track to a Master of Science in Nursing through accelerated, flexible coursework.

For those seeking a non-clinical role, online medical billing and coding with financial aid programs provide accessible training in high-demand administrative sectors of healthcare, often with financial support available.

Lastly, prospective nursing students concerned about admissions tests will find nursing schools that don't require teas or hesi can make the path into nursing school less stressful.

These varied online options ensure that aspiring healthcare professionals have multiple flexible routes to begin or advance their medical careers.

Best Scientists Citing Hervé Tilly

Trending Scientists